Pr Philippe Moreau
- Spécialité
- Hématologue, expert myélome multiple
- Hôpital
- Centre Hospitalier Universitaire de Nantes
- Derniers articles
-
- Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study. (24 févr. 2026)
- Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study. (20 janv. 2026)
- Teclistamab for Relapsed or Refractory Multiple Myeloma: A Review of Efficacy, Safety, Resistance Mechanisms and Future Directions. (13 janv. 2026)
- Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load. (18 déc. 2025)
- European Expert Recommendations on Teclistamab Management for Relapsed or Refractory Multiple Myeloma. (13 déc. 2025)